| HOME >> BIOLOGY >> TECHNOLOGY |
- Presentation to be Webcast -
MONTVALE, N.J., Feb. 6 /PRNewswire-FirstCall/ -- Synvista Therapeutics, Inc. (Amex: SYI) announced today that Noah Berkowitz, M.D., Ph.D., President and Chief Executive Officer of Synvista will present at the upcoming 10th Annual BIO CEO & Investor Conference on Monday, February 11, 2008 at 3:30 p.m. Eastern Time. The event will be held from February 11 - 13, 2008 at the Waldorf-Astoria Hotel in New York City.
Dr. Berkowitz will discuss the company's planned and/or ongoing Phase 2 initiatives for ALT-2074 in cardiovascular diseases and psoriasis, and alagebrium in heart failure and diabetic nephropathy. He will also provide an update of recent milestones.
The presentation will be simultaneously webcast and can be viewed live on the investor relations section of the Company's website at http://www.synvista.com. Participants are encouraged to log on to the webcast approximately five to ten minutes prior to the start of the presentation. It will be archived there after the event.
Note to Attendees: Synvista will be available for one-on-one meetings. Please arrange through BIO or by calling Kim Sutton Golodetz at Lippert/Heilshorn & Associates at 212-838-3777.
About Synvista Therapeutics
Synvista Therapeutics is a biopharmaceutical company developing small
molecule drugs to treat and prevent cardiovascular disease and to treat
nephropathy in people with diabetes. The Company has identified several
product candidates that it believes represent novel approaches to some of
the largest pharmaceutical markets. The Company's portfolio includes orally
bioavailable, organoselenium mimics of glutathione peroxid
'/>"/>
| SOURCE Synvista Therapeutics, Inc. Copyright©2008 PR Newswire. All rights reserved |